Literature DB >> 11775025

Rac regulates vascular endothelial growth factor stimulated motility.

N Soga1, J O Connolly, M Chellaiah, J Kawamura, K A Hruska.   

Abstract

During angiogenesis endothelial cells migrate towards a chemotactic stimulus. Understanding the mechanism of endothelial cell migration is critical to the therapeutic manipulation of angiogenesis and ultimately cancer prevention. Vascular endothelial growth factor (VEGF) is a potent chemotactic stimulus of endothelial cells during angiogenesis. The endothelial cell signal transduction pathway of VEGF represents a potential target for cancer therapy, but the mechanisms of post-receptor signal transduction including the roles of rho family GTPases in regulating the cytoskeletal effects of VEGF in endothelial cells are not understood. Here we analyze the mechanisms of cell migration in the mouse brain endothelial cell line (bEND3). Stable transfectants containing a tetracycline repressible expression vector were used to induce expression of Rac mutants. Endothelial cell haptotaxis was stimulated by constitutively active V12Rac on collagen and vitronectin coated supports, and chemotaxis was further stimulated by VEGF. Osteopontin coated supports were the most stimulatory to bEND3 haptotaxis, but VEGF was not effective in further increasing migration on osteopontin coated supports. Haptotaxis on support coated with collagen, vitronectin, and to a lesser degree osteopontin was inhibited by N17 Rac. N17 Rac expression blocked stimulation of endothelial cell chemotaxis by VEGF. As part of the chemotactic stimulation, VEGF caused a loss of actin organization at areas of cell-cell contact and increased stress fiber expression in endothelial cells which were directed towards pores in the transwell membrane. N17 Rac prevented the stimulation of cell-cell contact disruption and the stress fiber stimulation by VEGF. These data demonstrate two pathways of regulating endothelial cell motility, one in which Rac is activated by matrix/integrin stimulation and is a crucial modulator of endothelial cell haptotaxis. The other pathway, in the presence of osteopontin, is Rac independent. VEGF stimulated chemotaxis, is critically dependent on Rac activation. Osteopontin was a potent matrix activator of motility, and perhaps one explanation for the absence of a VEGF plus osteopontin effect is that osteopontin stimulated motility was inhibitory to the Rac pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11775025     DOI: 10.3109/15419060109080703

Source DB:  PubMed          Journal:  Cell Commun Adhes        ISSN: 1543-5180


  24 in total

1.  Vascular endothelial growth factor enhances macrophage clearance of apoptotic cells.

Authors:  Mark T Kearns; Samay Dalal; Sarah A Horstmann; Tiffany R Richens; Takeshi Tanaka; Jenna M Doe; Darren M Boe; Norbert F Voelkel; Laimute Taraseviciene-Stewart; William J Janssen; Chun G Lee; Jack A Elias; Donna Bratton; Rubin M Tuder; Peter M Henson; R William Vandivier
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

2.  Prediction of sphingosine 1-phosphate-stimulated endothelial cell migration rates using biochemical measurements.

Authors:  Shannon K Alford; Yumei Wang; Yunfeng Feng; Gregory D Longmore; Donald L Elbert
Journal:  Ann Biomed Eng       Date:  2010-04-01       Impact factor: 3.934

3.  Regulation of lymphatic-blood vessel separation by endothelial Rac1.

Authors:  Gabriela D'Amico; Dylan T Jones; Emma Nye; Karen Sapienza; Antoine R Ramjuan; Louise E Reynolds; Stephen D Robinson; Vassiliki Kostourou; Dolores Martinez; Deborah Aubyn; Richard Grose; Gareth J Thomas; Bradley Spencer-Dene; Daniel Zicha; Derek Davies; Victor Tybulewicz; Kairbaan M Hodivala-Dilke
Journal:  Development       Date:  2009-12       Impact factor: 6.868

Review 4.  Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.

Authors:  Sayed Shahabuddin Hoseini; Nai-Kong V Cheung
Journal:  Cancer Lett       Date:  2017-04-17       Impact factor: 8.679

5.  The bipartite rac1 Guanine nucleotide exchange factor engulfment and cell motility 1/dedicator of cytokinesis 180 (elmo1/dock180) protects endothelial cells from apoptosis in blood vessel development.

Authors:  Kathrin Schäker; Susanne Bartsch; Christian Patry; Sandra J Stoll; Jan-Luuk Hillebrands; Thomas Wieland; Jens Kroll
Journal:  J Biol Chem       Date:  2015-01-13       Impact factor: 5.157

6.  Permeability of endothelial and astrocyte cocultures: in vitro blood-brain barrier models for drug delivery studies.

Authors:  Guanglei Li; Melissa J Simon; Limary M Cancel; Zhong-Dong Shi; Xinying Ji; John M Tarbell; Barclay Morrison; Bingmei M Fu
Journal:  Ann Biomed Eng       Date:  2010-04-02       Impact factor: 3.934

Review 7.  Experimental methods and transport models for drug delivery across the blood-brain barrier.

Authors:  Bingmei M Fu
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

8.  Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension.

Authors:  Jennifer A Johnson; Anna R Hemnes; Daniel S Perrien; Manfred Schuster; Linda J Robinson; Santhi Gladson; Hans Loibner; Susan Bai; Tom R Blackwell; Yuji Tada; Julie W Harral; Megha Talati; Kirk B Lane; Karen A Fagan; James West
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-12-16       Impact factor: 5.464

9.  Endothelial cell-specific chemotaxis receptor (ecscr) promotes angioblast migration during vasculogenesis and enhances VEGF receptor sensitivity.

Authors:  Anjali Verma; Resham Bhattacharya; Indu Remadevi; Keguo Li; Kallal Pramanik; Ganesh V Samant; Mark Horswill; Chang Z Chun; Baofeng Zhao; Enfeng Wang; Robert Qing Miao; Debabrata Mukhopadhyay; Ramani Ramchandran; George A Wilkinson
Journal:  Blood       Date:  2010-01-19       Impact factor: 22.113

10.  Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent.

Authors:  Gabriela D'Amico; Stephen D Robinson; Mitchel Germain; Louise E Reynolds; Gareth J Thomas; George Elia; Garry Saunders; Marcus Fruttiger; Victor Tybulewicz; Georgia Mavria; Kairbaan M Hodivala-Dilke
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.